Improving treatment results with reference centres for rare cancers: where do we stand?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Cancer

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2017.02.006PMID 28384534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast cancer

  2017cited by this paper
• Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols

  2017cited by this paper
• Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France.

  2016cited by this paper
• The value of research collaborations and consortia in rare cancers.

  2016cited by this paper
• Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

  2015cited by this paper
• Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study.

  2015cited by this paper
• New clinical research strategies for rare gynecologic malignancies

  2015cited by this paper
• The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?

  2014cited by this paper
• International Journal of Gynecological Cancer. Editorial.

  2014cited by this paper
• Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region

  2013cited by this paper
• Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project.

  2013cited by this paper
• International Rare Cancers Initiative (IRCI)

  2013cited by this paper
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

  2012cited by this paper
• Pazopanib for metastatic soft-tissue sarcoma.

  2012cited by this paper
• A role for maintenance therapy in managing sarcoma.

  2012cited by this paper
• Rare cancers are not so rare: the rare cancer burden in Europe.

  2011cited by this paper
• The burden of rare cancers in Europe.

  2010cited by this paper
• Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts.

  2009cited by this paper
• Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

  2008cited by this paper
• Survival from rare cancer in adults: a population-based study.

  2006cited by this paper
• ON THE ACTION OF THE HEART.

  1831cited by this paper

• Intratumor Heterogeneity and Clonal Evolution in Sarcomas: Molecular, Cellular, and Functional Drivers of Therapy Resistance.

  2026cites this paper
• Organizing Contemporary Oncology Care Together - a Scoping Review on Multi-hospital Oncology Networks.

  2025cites this paper
• Cancer of the vagina: 2025 update

  2025cites this paper
• The burden of rare cancers among adults in the Canton of Geneva, Switzerland, from 2011 to 2020

  2025cites this paper
• Diagnostic work-up of an incidental ultra-rare tumour, epithelioid haemangioendothelioma, in a Danish diagnostic centre

  2025cites this paper
• Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review

  2025cites this paper
• An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers

  2025cites this paper
• Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology

  2025cites this paper
• Clinical trials involving rare gynaecological cancers.

  2024cites this paper
• Diagnostic trajectories of patients with rare cancer in the Netherlands: results from a nationwide cross-sectional survey

  2024influential citation
• Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

  2024cites this paper
• Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures

  2024cites this paper
• The Role of Patient Advocates and Sarcoma Community Initiatives in Musculoskeletal Oncology. Moving towards Evidence-Based Advocacy to Empower Evidence- Based Medicine.

  2023cites this paper
• Measuring Health-Related Quality of Life in Solid Rare Cancer Patients: A Study Protocol

  2023cites this paper
• The solitary versus supported experience: Care inequality between rare and common cancer patients

  2023cites this paper
• NUT carcinoma of the submandibular gland: A case report

  2023cites this paper
• LEIOMYOSARCOMA AND LIPOSARCOMA IN YOUNG PATIENTS: THE NATIONAL NETSARC+ NETWORK EXPERIENCE

  2023cites this paper
• Primary Small Cell Carcinoma of the Breast: When a Rare Tumour is Real

  2023cites this paper
• Challenging gestational trophoblastic disease cases and mimics: An exemplar for the management of rare tumours.

  2023cites this paper
• How Is the Spectrum of Sarcoma Surgery Assessed?

  2023cites this paper
• Quality of care and quality of life as experienced by patients with advanced cancer of a rare tumour type: results of the multicentre observational eQuiPe study

  2023cites this paper
• Management of malignant dysgerminoma of the ovary

  2022cites this paper
• Survival analysis of cancer patients in Portugal following the reference centre model implementation

  2022cites this paper
• The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands.

  2022cites this paper
• Application of precision medicine in clinical routine in haematology—Challenges and opportunities

  2022cites this paper
• Biology-Guided Precision Medicine in Rare Cancers: Lessons from Sarcomas and Neuroendocrine Tumours.

  2022cites this paper
• Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.

  2022cites this paper
• Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership

  2022cites this paper
• Rare disease education in Europe and beyond: time to act

  2022cites this paper
• Rare cancers and cancer of unknown primary: Here's what you should know!

  2021cites this paper
• Interdisciplinary team science to understand and intercept rare cancers

  2021cites this paper
• Unmet supportive care needs of patients with rare cancer: A systematic review.

  2021cites this paper
• Locally aggressive rarely metastazing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network.

  2021cites this paper
• Importance of guidelines and networking for the management of rare gynecological cancers

  2021cites this paper
• Supportive care needs of patients living with an extremely rare and unpredictable cancer: The Epithelioid Haemangioendothelioma patient experience.

  2021cites this paper
• Precision medicine for female-specific cancers: Strategies, challenges, and solutions

  2021cites this paper
• Diagnosed with a Rare Cancer: Experiences of Adult Sarcoma Survivors with the Healthcare System—Results from the SURVSARC Study

  2021cites this paper
• The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study

  2021cites this paper
• Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey

  2020cites this paper
• Detailed overview on rare malignant ovarian tumors.

  2020cites this paper
• A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries

  2020cites this paper
• Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer

  2020cites this paper
• Rare Tumours

  2019cites this paper
• Cancer care in Brazil: structure and geographical distribution

  2019cites this paper
• Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes.

  2019cites this paper
• Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world

  2019cites this paper
• Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation.

  2019cites this paper
• A call to action: Why sarcoma surgery needs to be centralized

  2018cites this paper
• Survival of adults with cancers of bone or soft tissue in Europe-Report from the EUROCARE-5 study.

  2018cites this paper
• Working to improve the management of sarcoma patients across Europe: a policy checklist

  2018cites this paper
• Cost-effectiveness of healthcare interventions for rare cancers: Evidence from a systematic literature review and meta-analysis

  2018cites this paper
• Geographic variation in surgical practice patterns and outcomes for resected nonmetastatic gastric cancer in Ontario.

  2018cites this paper
• Building Eminence through Evidence

  2017cites this paper
• Transposition and implementation of EU rare disease policy in Eastern Europe

  2017cites this paper
• Epidemiology of rare cancers and inequalities in oncologic outcomes.

  2017cites this paper
• Treatment challenges in and outside a network setting: Soft tissue sarcomas.

  2017cites this paper